Collaboration expands national initiative designed to accelerate the discovery, validation, and delivery of non-invasive neuroprotective therapies Cognito Therapeutics, a late clinical-stage ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a leader in technology-based therapeutic interventions for neurodegenerative diseases, today announced a publication demonstrating structural ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced robust lobe-specific changes in white ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The idea behind the device is to ...

Alzheimer’s disease serves as bookends to Brent Vaughan’s career so far. Twenty years ago, he worked for a Bay Area biotech whose pipeline included small molecules in development for the ...

Cognito Therapeutics has delivered clinical data from its digital treatment for patients with Alzheimer’s disease—which relies on light and sound to stimulate specific electrical frequencies in the ...

After demonstrating last year that its light- and sound-based therapy could help improve memory and cognition among Alzheimer’s patients in an early clinical study, Cognito Therapeutics is going a ...

Cognito Therapeutics, a startup using visual and auditory stimulation to treat neurodegenerative disorders, scored $73 million in a Series B funding round led by FoundersX Ventures, bringing its total ...

Cognito Therapeutics and the West Virginia University Rockefeller Neuroscience Institute (RNI), announced today the launch of the first Brain Health Collaboratory, a new model designed to accelerate ...

CAMBRIDGE, Mass. and NEW ORLEANS – March 25, 2026 - Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, ...